Entera Bio

Update in progress

ENTX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Entera Bio Ltd. is a clinical‑stage company focused on oral peptide and protein replacement therapies in Israel and abroad. It is advancing EB613, an oral teriparatide, in Phase II for osteoporosis and Phase I for stress fractures. EB612 targets hypoparathyroidism in Phase I, while EB618 is a GLP‑1/glucagon dual agonist in Phase I for obesity and related disorders. GLP‑2 is in Phase I for short bowel syndrome. It collaborates with OPKO Biologics on LA‑PTH and oral dual agonist GLP‑1/glucagon. Founded in 2009, based in Jerusalem.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.27; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive